icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Renewal of inclusion
Clinical Benefit
Substantial
The actual benefit of DOTAREM remains substantial.
Clinical Added Value
minor
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification.
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
Tu0kf6HMKwhuDJYx